Breaking News Instant updates and real-time market news.

ACOR

Acorda Therapeutics

$27.15

1 (3.82%)

07:26
08/07/18
08/07
07:26
08/07/18
07:26

Acorda Therapeutics resumed with a Hold at Stifel

Stifel analyst Paul Matteis resumed coverage of Acorda Therapeutics with a Hold rating and a $25 price target, stating that his long-term confidence in Inbrija is balanced by his expectation that the launch may ramp linearly and could lag 2019/2020 consensus expectations.

  • 05

    Oct

ACOR Acorda Therapeutics
$27.15

1 (3.82%)

02/05/18
JEFF
02/05/18
NO CHANGE
Target $25
JEFF
Hold
Acorda remains takeover candidate after competitor data, says Jefferies
Jefferies analyst Michael Yee believes the positive Phase III topline results from Acorda Therapeutics (ACOR) competitor Sunovion for APL-130277 in Parkinson's patients came in as expected. While APL-130277 data compares favorably over Inbrija's 3.92 point difference at week 12, Yee cautions to compare directly head-to-head since patient baseline characteristics could be different. Acorda remains a "reasonably likely" acquisition candidate in 2018 given its $300M-$500M-plus Parkinson's asset Inbrija, Yee tells investors in a research note. The analyst does not think Biogen (BIIB) should buy the company, but sees other potential suitors in AbbVie (ABBV), Allergan (AGN), Mitsubishi, Roche (RHHBY) and Shire (SHPG). He believes a takeover price could be north of $2B. Yee keeps a Hold rating on Acorda with a $25 price target.
02/15/18
PIPR
02/15/18
UPGRADE
PIPR
Overweight
Acorda Therapeutics upgraded to Overweight from Neutral at Piper Jaffray
02/16/18
PIPR
02/16/18
UPGRADE
Target $37
PIPR
Overweight
Piper upgrades Acorda to Overweight on potential in Parkinson's
Piper Jaffray analyst Charles Duncan last night upgraded Acorda Therapeutics and raised his price target for the shares to $37 from $32. The analyst, based on diligence in the Parkinson's space, has "enhanced conviction" that Inbrija can be a $700M-$800M drug in the U.S. alone. He sees a "risk-reduced regulatory path" ahead in the U.S. and Europe. Acorda closed yesterday down 50c to $25.10.
07/30/18
CANT
07/30/18
NO CHANGE
Target $17
CANT
Neutral
Acorda's last patent for Ampyra expires today, says Cantor Fitzgerald
Exclusivity for the last valid Ampyra patent expires today, Cantor Fitzgerald analyst William Tanner tells investors in a research note. The analyst points out that four other Orange Book-listed patents were ruled invalid by a District Court in 2017. Shares of Acorda Therapeutics are down 17% since the company disclosed on July 25 that a U.S. Court of Appeals denied a motion for an injunction pending its appeal of that decision, Tanner writes. He notes that exclusivity expiration of the last valid patent coupled with the injunction denial means that generic fampridine developers could launch their versions. The analyst reiterates a Neutral rating on Acorda with a $17 price target.

TODAY'S FREE FLY STORIES

CASI

Casi Pharmaceuticals

$3.33

0.025 (0.76%)

16:47
11/14/18
11/14
16:47
11/14/18
16:47
Syndicate
Casi Pharmaceuticals files to sell 9.09M shares of common stock for holders »

The shares consist of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:46
11/14/18
11/14
16:46
11/14/18
16:46
General news
API crude inventories for week of November 9 »

API reports that crude…

AJX

Great Ajax

$13.70

0.05 (0.37%)

16:45
11/14/18
11/14
16:45
11/14/18
16:45
Syndicate
Great Ajax files to sell convertible senior notes due 2024, no amount given »

The Notes represent an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:45
11/14/18
11/14
16:45
11/14/18
16:45
General news
Breaking General news story  »

Federal Reserve Chairman…

16:45
11/14/18
11/14
16:45
11/14/18
16:45
General news
Breaking General news story  »

Dallas Federal Reserve…

BBT

BB&T

$50.54

-0.53 (-1.04%)

16:44
11/14/18
11/14
16:44
11/14/18
16:44
Earnings
BB&T sees FY19 revenue growth up 2%-4% »

Sees FY19 credit loss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 18

    Oct

ADP

ADP

$142.75

-2.11 (-1.46%)

16:43
11/14/18
11/14
16:43
11/14/18
16:43
Hot Stocks
Breaking Hot Stocks news story on ADP »

Ackman's Pershing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$95.02

-0.61 (-0.64%)

, UTX

United Technologies

$128.89

-0.245 (-0.19%)

16:41
11/14/18
11/14
16:41
11/14/18
16:41
Hot Stocks
Breaking Hot Stocks news story on Lowe's, United Technologies »

Ackman's Pershing…

LOW

Lowe's

$95.02

-0.61 (-0.64%)

UTX

United Technologies

$128.89

-0.245 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

FANG

Diamondback Energy

$108.75

0.92 (0.85%)

, EGN

Energen

$69.80

0.68 (0.98%)

16:40
11/14/18
11/14
16:40
11/14/18
16:40
Hot Stocks
Diamondback, Energen say ISS, Glass Lewis recommend merger »

Diamondback Energy, Inc.…

FANG

Diamondback Energy

$108.75

0.92 (0.85%)

EGN

Energen

$69.80

0.68 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDTI

CDTi

$1.49

-0.03 (-1.97%)

16:35
11/14/18
11/14
16:35
11/14/18
16:35
Hot Stocks
Breaking Hot Stocks news story on CDTi »

Clean Diesel Techologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WNC

Wabash

$15.20

0.11 (0.73%)

16:33
11/14/18
11/14
16:33
11/14/18
16:33
Hot Stocks
Wabash increases dividend 6.7% to 8c per share »

Wabash approved a 6.7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EYE

National Vision

$41.79

0.72 (1.75%)

16:32
11/14/18
11/14
16:32
11/14/18
16:32
Syndicate
Breaking Syndicate news story on National Vision »

National Vision files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTX

Cytori Therapeutics

$0.34

-0.0064 (-1.87%)

16:30
11/14/18
11/14
16:30
11/14/18
16:30
Earnings
Cytori Therapeutics reports Q3 EPS (27c), consensus (30c) »

Reports Q3 revenue $858K,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

16:30
11/14/18
11/14
16:30
11/14/18
16:30
Options
Preliminary option volume of 23.4M today »

Preliminary option volume…

APRN

Blue Apron

$1.17

-0.055 (-4.51%)

16:28
11/14/18
11/14
16:28
11/14/18
16:28
Downgrade
Blue Apron rating change  »

Blue Apron downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 28

    Nov

ADS

Alliance Data

$199.76

-5.49 (-2.67%)

16:27
11/14/18
11/14
16:27
11/14/18
16:27
Initiation
Alliance Data initiated  »

Alliance Data initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

ADP

ADP

$142.75

-2.11 (-1.46%)

16:26
11/14/18
11/14
16:26
11/14/18
16:26
Initiation
ADP initiated  »

ADP initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVOP

EVO Payments

16:26
11/14/18
11/14
16:26
11/14/18
16:26
Initiation
EVO Payments initiated  »

EVO Payments initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CATM

Cardtronics

$33.01

-0.01 (-0.03%)

16:25
11/14/18
11/14
16:25
11/14/18
16:25
Initiation
Cardtronics initiated  »

Cardtronics initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFS

Smart & Final Stores

$4.96

-0.2 (-3.88%)

16:25
11/14/18
11/14
16:25
11/14/18
16:25
Hot Stocks
Smart & Final Stores reports Q3 gross margin up 8.7% y/y »

Gross margin was $232.4M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

FIS

FIS

$104.57

-0.26 (-0.25%)

16:25
11/14/18
11/14
16:25
11/14/18
16:25
Initiation
FIS initiated  »

FIS initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

16:25
11/14/18
11/14
16:25
11/14/18
16:25
Conference/Events
Federal Reserve Bank of Dallas president participates in a discussion »

Federal Reserve Bank of…

KBH

KB Home

$20.80

-0.135 (-0.64%)

16:25
11/14/18
11/14
16:25
11/14/18
16:25
Conference/Events
KB Home to hold a conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

YUMA

Yuma Energy

$0.29

-0.0088 (-2.98%)

16:24
11/14/18
11/14
16:24
11/14/18
16:24
Hot Stocks
Yuma Energy retains Seaport Global to explore alternatives, liquidity options »

Yuma Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDC

First Data

$17.83

-0.18 (-1.00%)

16:24
11/14/18
11/14
16:24
11/14/18
16:24
Initiation
First Data initiated  »

First Data initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 03

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.